Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30887808 | 0.87 | HDAC1 (0.54) | HDAC1HDAC2LTA4HALDH1A1MAPT | |
| SCHEMBL6103 | 0.81 | GPR119 (0.42) | HDAC1GAAALDH1A1NPC1RAB9A | |
| SCHEMBL6447258 | 0.81 | HDAC1 (0.52) | HDAC1GAAALDH1A1NPC1RAB9A | |
| SCHEMBL6167 | 0.79 | ADRB2 (0.53) | HDAC1HDAC2HDAC3LTA4HGAA | |
| SCHEMBL6445761 | 0.78 | ESRRG (0.55) | GAA | |
| SCHEMBL4632779 | 0.78 | CA12 (0.60) | GAAALDH1A1NPC1RAB9A | |
| SCHEMBL9971059 | 0.77 | GAA (0.51) | GAAALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL29800530 | 0.77 | CA12 (0.48) | GAANPC1RAB9A | |
| SCHEMBL6236607 | 0.77 | GAA (0.51) | GAAALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL9971046 | 0.77 | GAA (0.50) | HDAC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1310905-C | Antivirally active heterocyclic azahexane derivatives | NOVARTIS AG (CH) | 2007-04-18 | — | — | CN | disclosed |
| CN-1616453-A | Antivirally active heterocyclic azahexane derivatives | NOVARTIS AG (CH) | 2005-05-18 | — | — | CN | disclosed |
| CN-1193010-C | Heterocyclic azahexane derivatives with antiviral activity | NOVARTIS AG (CH) | 2005-03-16 | — | — | CN | disclosed |
| EP-0900210-B1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | NOVARTIS AG (CH) | 2005-02-09 | — | — | EP | disclosed |
| CN-1082508-C | Heterocyclic azahexane derivatives with antiviral activity | NOVARTIS AG (CH) | 2002-04-10 | — | — | CN | disclosed |
| CN-1319587-A | Heterocyclic azahexane derivatives with antiviral activity | NOVARTIS AG (CH) | 2001-10-31 | — | — | CN | disclosed |
| US-6300519-B1 | REACTING HYDRAZINE DERIVATIVE WITH EPOXIDE COMPOUND | NOVARTIS FINANCE CORPORATION | 2001-10-09 | — | — | US | disclosed |
| US-6166004-A | Combinations of HIV protease inhibitors with reverse transcriptase inhibitors | NOVARTIS FINANCE CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| US-6110946-A | AN ENZYME INHIBITORS OF RETROVIRAL ASPARTATE PROTEASE FOR THE TREATMENT OF AIDS | NOVARTIS FINANCE CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| CN-1216539-A | Heterocyclic azahexane derivatives with antiviral activity | NOVARTIS AG (CH) | 1999-05-12 | — | — | CN | disclosed |
| EP-0900210-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | Novartis AG (CH) | 1999-03-10 | — | — | EP | disclosed |
| US-5849911-A | Antivirally active heterocyclic azahexane derivatives | NOVARTIS FINANCE CORPORATION (US) | 1998-12-15 | — | — | US | disclosed |
| WO-1997040029-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | NOVARTIS AG (CH) | 1997-10-30 | — | — | WO | disclosed |